Cargando…

Erratum: Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194440/ http://dx.doi.org/10.4103/0970-2113.316001

Ejemplares similares

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Erratum to spliceosome-associated protein 130: a novel biomarker for idiopathic pulmonary fibrosis
Publicado: (2021)

Erratum: Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry
Publicado: (2023)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Erratum to: Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer
por: Stella, Giulia M., et al.
Publicado: (2017)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis
por: Nemoto, Masahiro, et al.
Publicado: (2021)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
por: Moor, C. C., et al.
Publicado: (2020)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
por: Nakano, Akiko, et al.
Publicado: (2018)

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future
por: Nathan, Steven D.
Publicado: (2019)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes
por: O’Dwyer, David N., et al.
Publicado: (2017)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jsm553q24qhj51289o5jjpe0l0